Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Inclusion Criteria:Adults ≥18 years of ageHistory of nephrotic syndrome, characterized by heavy proteinuria and hypoalbuminemiaRecent nephrotic relapse in the 6 months prior to screeningEstimated glomerular filtration rate (eGFR) of ≥45 during screeningNot pregnant, breastfeeding, or lactating and agree to use a highly effective method of acceptable contraceptive for the trial duration, if applicableExclusion Criteria:Subjects with collapsing FSGS focal segmental glomerulosclerosis (FSGS)Known secondary cause of nephrotic syndrome (e.g., diabetic nephropathy, systemic lupus erythematous, sickle cell anemia, malignancy, drug-induced, malaria)History of kidney transplantation or other solid organ transplantationHistory of any unstable chronic diseases/conditions, clinically significant abnormalities, or findings, that in the opinion of the Investigator, could compromise subject safety or affect the conduct of the trial